Loading clinical trials...
Loading clinical trials...
To ascertain the safety and efficacy of Istodax® in actual clinical settings in patients with relapsed or refractory peripheral T-cell lymphoma (PTCL) who receive Istodax. 1. Planned registration per...
Bring this clarity to your next appointment.
Keep all your medical notes and next steps in one place.
Lead Sponsor
Celgene
NCT06561048 · Peripheral T-Cell Lymphoma, Not Otherwise Specified, Angioimmunoblastic T-cell Lymphoma, and more
NCT06947967 · Lymphoma, T-Cell, Peripheral
NCT05137847 · Lymphoma, T-cell, Peripheral, Lymphoma, T-cell, Cutaneous
NCT03049449 · Lymphoma, Large-Cell, Anaplastic, Enteropathy-Associated T-Cell Lymphoma, and more
NCT03302728 · Lymphoma, T-Cell, Cutaneous, Lymphoma, T-Cell, Peripheral, and more
Nihon Seimei Hospital
Osaka
Use Clareo to keep notes, questions, trial details, and next steps organized before and after appointments.
Data Source & Attribution
This clinical trial information is sourced from ClinicalTrials.gov, a service of the U.S. National Institutes of Health.
Modifications: This data has been reformatted for display purposes. Eligibility criteria have been parsed into inclusion/exclusion sections. Location data has been geocoded to enable distance-based search. For the authoritative and most current information, please visit ClinicalTrials.gov.
Neither the United States Government nor Clareo Health make any warranties regarding the data. Check ClinicalTrials.gov frequently for updates.
View ClinicalTrials.gov Terms and Conditions